Dendrimer: An update on recent developments and future opportunities for the brain tumors diagnosis and treatment
Open Access
- 16 March 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1159131
- https://doi.org/10.3389/fphar.2023.1159131
Abstract
A brain tumor is an uncontrolled cell proliferation, a mass of tissue composed of cells that grow and divide abnormally and appear to be uncontrollable by the processes that normally control normal cells. Approximately 25,690 primary malignant brain tumors are discovered each year, 70% of which originated from the glial cells. It has been observed that the blood-brain barrier (BBB) limits the distribution of drugs into the tumour environment, which complicates the oncological therapy of malignant brain tumours. Numerous studies have stated that nanocarriers have demonstrated significant therapeutic efficacy for the brain diseases. The present review which is based on a non-systematic search of the existing literature offers an update on the existing knowledge of types of dendrimers, synthesis methods, and mechanisms of action in relation to brain tumors. It also discusses the use of dendrimers in the diagnosis and treatment of brain tumours and the future possibilities of dendrimers. Dendrimers are of particular interest in the diagnosis and treatment of brain tumours because they can transport biochemical agents to the tumour via the BBB and into the brain after systemic administration. Novel therapeutics such as prolonged release of drugs, immunotherapy and antineoplastic effects are developed using dendrimers. The use of PAMAM, PPI, PLL and surface engineered dendrimers has proven revolutionary in the effective diagnosis and treatment of brain tumours.This publication has 212 references indexed in Scilit:
- Nanomaterials in Stroke TreatmentStroke, 2013
- Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-deliveryBiomaterials, 2013
- RGD-modified PEG–PAMAM–DOX conjugates: In vitro and in vivo studies for gliomaEuropean Journal of Pharmaceutics and Biopharmaceutics, 2011
- Peptide and glycopeptide dendrimers and analogous dendrimeric structures and their biomedical applicationsAmino Acids, 2010
- Triazine Dendrimers as Nonviral Vectors for in Vitro and in Vivo RNAi: The Effects of Peripheral Groups and Core Structure on Biological ActivityMolecular Pharmaceutics, 2010
- Targeting the insulin receptor: nanoparticles for drug delivery across the blood–brain barrier (BBB)Journal of Drug Targeting, 2010
- Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to ClinicCritical Reviews in Therapeutic Drug Carrier Systems, 2009
- Macromolecular TherapeuticsClinical Pharmacokinetics, 2003
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Water-Soluble 99mTc-Labeled Dendritic Novel Porphyrins Tumor Imaging and DiagnosisBiochemical and Biophysical Research Communications, 2001